Pharmalgen for the treatment of bee and wasp venom allergy

  • Technology appraisal guidance
  • TA246
  • Published: 
Download guidance (PDF)

7 Sources of evidence considered by the Committee

The assessment report for this appraisal was prepared by Liverpool Reviews and Implementation Group (LRiG):

  • Hockenhull JC, Elremeli M, Cherry MG et al. The clinical and cost effectiveness of Pharmalgen for the treatment of bee and wasp venom allergy, July 2011.

The following organisations accepted the invitation to participate in this appraisal as consultees and commentators. They were invited to comment on the draft scope, assessment report and the appraisal consultation document (ACD). Manufacturers or sponsors, professional or specialist, patient or carer groups, and other consultees, were also invited to make written submissions and have the opportunity to appeal against the final appraisal determination.

Manufacturers or sponsors:

  • ALK-Abelló

Professional or specialist, and patient or carer groups:

  • Anaphylaxis Campaign

  • British Society for Allergy and Clinical Immunology

  • Royal College of Nursing

  • Royal College of Paediatrics and Child Health

  • Royal College of Pathologists

  • Royal College of Physicians

Other consultees:

  • Department of Health

  • NHS Tower Hamlets

  • Welsh Government

Commentator organisations (without the right of appeal):

  • British National Formulary

  • Commissioning Support Appraisals Service

  • David Hide Asthma and Allergy Research Centre

  • Department of Health Social Services and Public Safety for Northern Ireland

  • Healthcare Improvement Scotland

  • Lincoln Medical

The following individuals were selected from clinical specialist and patient expert nominations from the non-manufacturer or sponsor consultees and commentators. They participated in the Appraisal Committee discussions and provided evidence to inform the Appraisal Committee's deliberations. They gave their expert personal view on Pharmalgen by attending the initial Committee discussion and/or providing written evidence to the Committee. They were also invited to comment on the ACD.

  • Dr Nicola Braithwaite, Consultant Paediatric Allergist, nominated by the Royal College of Paediatrics and Child Health – clinical specialist

  • Dr Pamela Ewan, Consultant Allergist, nominated by the British Society for Allergy and Clinical Immunology – clinical specialist

  • Dr Thirumala Krishna, Consultant Allergist and Immunologist, nominated by the British Society for Allergy and Clinical Immunology – clinical specialist

  • Moira Austin, nominated by the Anaphylaxis Campaign – patient specialist

  • David Glaser, nominated by the Anaphylaxis Campaign – patient specialist

Representatives from the following manufacturers or sponsors attended Committee meetings. They contributed only when asked by the Committee chair to clarify specific issues and comment on factual accuracy. They were also invited to comment on the ACD.

  • ALK-Abelló